• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Dental Pain - Pipeline Review, H2 2012 Product Image

Dental Pain - Pipeline Review, H2 2012

  • Published: November 2012
  • 50 pages
  • Global Markets Direct

Dental Pain – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Dental Pain - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Dental Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dental Pain. Dental Pain - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dental Pain.
- A review of the Dental Pain products under development by companies and universities/research institutes based on information derived from READ MORE >

2
List of Tables 4
List of Figures 5
Introduction 6
REPORT COVERAGE 6
Dental Pain Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Dental Pain 8
Dental Pain Therapeutics under Development by Companies 10
Dental Pain Therapeutics under Investigation by Universities/Institutes 12
Late Stage Products 13
Comparative Analysis 13
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Pre-Clinical Stage Products 16
Comparative Analysis 16
Dental Pain Therapeutics – Products under Development by Companies 17
Dental Pain Therapeutics – Products under Investigation by Universities/Institutes 18
Companies Involved in Dental Pain Therapeutics Development 19
Piramal Healthcare Limited 19
Novartis AG 20
Pfizer Inc. 21
Menarini Group 22
Array BioPharma Inc. 23
Xenon Pharmaceuticals Inc. 24
RaQualia Pharma Inc. 25
Dental Pain – Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Combination Products 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ARRY-797 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
P-3914 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
diclofenac sodium - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
XPF-001 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
ketamine hydrochloride - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SAF-312-A - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PF-05089771 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Dexketoprofen Trometamol + Tramadol Hydrochloride - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
lornoxicam - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RQ-00317076 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Dental Pain Therapeutics – Drug Profile Updates 44
Dental Pain Therapeutics – Discontinued Products 45
Dental Pain Therapeutics - Dormant Products 46
Dental Pain – Product Development Milestones 47
Featured News & Press Releases 47
Jun 21, 2012: Iroko Pharma Announces Phase III Study Results Of Diclofenac 47
Nov 04, 2011: Phase II Results For Nano-formulated NSAIDs Under Development At Iroko Pharmaceuticals To Be Reported At ACR Meeting 48
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 50
Disclaimer 50

List of Tables
Number of Products Under Development for Dental Pain, H2 2012 8
Products under Development for Dental Pain – Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 11
Number of Products under Investigation by Universities/Institutes, H2 2012 12
Comparative Analysis by Late Stage Development, H2 2012 13
Comparative Analysis by Mid Clinical Stage Development, H2 2012 14
Comparative Analysis by Early Clinical Stage Development, H2 2012 15
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 16
Products under Development by Companies, H2 2012 17
Products under Investigation by Universities/Institutes, H2 2012 18
Piramal Healthcare Limited, H2 2012 19
Novartis AG, H2 2012 20
Pfizer Inc., H2 2012 21
Menarini Group, H2 2012 22
Array BioPharma Inc., H2 2012 23
Xenon Pharmaceuticals Inc., H2 2012 24
RaQualia Pharma Inc., H2 2012 25
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Stage and Molecule Type, H2 2012 31
Dental Pain Therapeutics – Drug Profile Updates 44
Dental Pain Therapeutics – Discontinued Products 45
Dental Pain Therapeutics – Dormant Products 46

List of Figures
Number of Products under Development for Dental Pain, H2 2012 8
Products under Development for Dental Pain – Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 12
Late Stage Products, H2 2012 13
Mid Clinical Stage Products, H2 2012 14
Early Clinical Stage Products, H2 2012 15
Pre-Clinical Stage Products, H2 2012 16
Assessment by Monotherapy Products, H2 2012 26
Assessment by Combination Products, H2 2012 27
Assessment by Route of Administration, H2 2012 28
Assessment by Stage and Route of Administration, H2 2012 29
Assessment by Molecule Type, H2 2012 30
Assessment by Stage and Molecule Type, H2 2012 31

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos